Selected research
Industry Research
Afatinib Maleate Tablets Industry Research Report 2026
Market perspective
The global Afatinib Maleate Tablets market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Afatinib Maleate Tablets market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Afatinib Maleate Tablets market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Afatinib Maleate Tablets market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Afatinib Maleate Tablets include Yangtze River Pharm, Qingfeng Medicine Group, Qilu Pharmaceutical, Beacon Pharmaceuticals, Kelun－Kazpharm, Hansoh Pharmaceuticak, Chia Tai-Tianqing and Boehringer Ingelheim International GmbH, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Afatinib Maleate Tablets market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Afatinib Maleate Tablets.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Afatinib Maleate Tablets Market by Company
Yangtze River Pharm
Qingfeng Medicine Group
Qilu Pharmaceutical
Beacon Pharmaceuticals
Kelun－Kazpharm
Hansoh Pharmaceuticak
Chia Tai-Tianqing
Boehringer Ingelheim International GmbH
Afatinib Maleate Tablets Segment by Type
50mg
40mg
30mg
20mg
Afatinib Maleate Tablets Segment by Application
Hospital
Clinic
Others
Afatinib Maleate Tablets Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Afatinib Maleate Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Afatinib Maleate Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Afatinib Maleate Tablets.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Afatinib Maleate Tablets companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 50mg
- 40mg
- 30mg
- 20mg
Applications
- Hospital
- Clinic
- Others
Companies covered
- Yangtze River Pharm
- Qingfeng Medicine Group
- Qilu Pharmaceutical
- Beacon Pharmaceuticals
- Kelun－Kazpharm
- Hansoh Pharmaceuticak
- Chia Tai-Tianqing
- Boehringer Ingelheim International GmbH
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Afatinib Maleate Tablets by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 50mg
- 2.2.3 40mg
- 2.2.4 30mg
- 2.2.5 20mg
- 2.3 Afatinib Maleate Tablets by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Afatinib Maleate Tablets Breakdown Data by Type
- 3.1 Global Afatinib Maleate Tablets Historic Market Size by Type (2021-2026)
- 3.2 Global Afatinib Maleate Tablets Forecasted Market Size by Type (2027-2032)
4 Afatinib Maleate Tablets Breakdown Data by Application
- 4.1 Global Afatinib Maleate Tablets Historic Market Size by Application (2021-2026)
- 4.2 Global Afatinib Maleate Tablets Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Afatinib Maleate Tablets Market Perspective (2021-2032)
- 5.2 Global Afatinib Maleate Tablets Growth Trends by Region
- 5.2.1 Global Afatinib Maleate Tablets Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Afatinib Maleate Tablets Historic Market Size by Region (2021-2026)
- 5.2.3 Afatinib Maleate Tablets Forecasted Market Size by Region (2027-2032)
- 5.3 Afatinib Maleate Tablets Market Dynamics
- 5.3.1 Afatinib Maleate Tablets Industry Trends
- 5.3.2 Afatinib Maleate Tablets Market Drivers
- 5.3.3 Afatinib Maleate Tablets Market Challenges
- 5.3.4 Afatinib Maleate Tablets Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Afatinib Maleate Tablets Players by Revenue
- 6.1.1 Global Top Afatinib Maleate Tablets Players by Revenue (2021-2026)
- 6.1.2 Global Afatinib Maleate Tablets Revenue Market Share by Players (2021-2026)
- 6.2 Global Afatinib Maleate Tablets Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Afatinib Maleate Tablets Head Office and Area Served
- 6.4 Global Afatinib Maleate Tablets Players, Product Type & Application
- 6.5 Global Afatinib Maleate Tablets Manufacturers Established Date
- 6.6 Global Afatinib Maleate Tablets Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Afatinib Maleate Tablets Market Size (2021-2032)
- 7.2 North America Afatinib Maleate Tablets Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Afatinib Maleate Tablets Market Size by Country (2021-2026)
- 7.4 North America Afatinib Maleate Tablets Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Afatinib Maleate Tablets Market Size (2021-2032)
- 8.2 Europe Afatinib Maleate Tablets Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Afatinib Maleate Tablets Market Size by Country (2021-2026)
- 8.4 Europe Afatinib Maleate Tablets Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Afatinib Maleate Tablets Market Size (2021-2032)
- 9.2 Asia-Pacific Afatinib Maleate Tablets Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Afatinib Maleate Tablets Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Afatinib Maleate Tablets Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Afatinib Maleate Tablets Market Size (2021-2032)
- 10.2 South America Afatinib Maleate Tablets Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Afatinib Maleate Tablets Market Size by Country (2021-2026)
- 10.4 South America Afatinib Maleate Tablets Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Afatinib Maleate Tablets Market Size (2021-2032)
- 11.2 Middle East & Africa Afatinib Maleate Tablets Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Afatinib Maleate Tablets Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Afatinib Maleate Tablets Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Yangtze River Pharm
- 12.1.1 Yangtze River Pharm Company Information
- 12.1.2 Yangtze River Pharm Business Overview
- 12.1.3 Yangtze River Pharm Revenue in Afatinib Maleate Tablets Business (2021-2026)
- 12.1.4 Yangtze River Pharm Afatinib Maleate Tablets Product Portfolio
- 12.1.5 Yangtze River Pharm Recent Developments
- 12.2 Qingfeng Medicine Group
- 12.2.1 Qingfeng Medicine Group Company Information
- 12.2.2 Qingfeng Medicine Group Business Overview
- 12.2.3 Qingfeng Medicine Group Revenue in Afatinib Maleate Tablets Business (2021-2026)
- 12.2.4 Qingfeng Medicine Group Afatinib Maleate Tablets Product Portfolio
- 12.2.5 Qingfeng Medicine Group Recent Developments
- 12.3 Qilu Pharmaceutical
- 12.3.1 Qilu Pharmaceutical Company Information
- 12.3.2 Qilu Pharmaceutical Business Overview
- 12.3.3 Qilu Pharmaceutical Revenue in Afatinib Maleate Tablets Business (2021-2026)
- 12.3.4 Qilu Pharmaceutical Afatinib Maleate Tablets Product Portfolio
- 12.3.5 Qilu Pharmaceutical Recent Developments
- 12.4 Beacon Pharmaceuticals
- 12.4.1 Beacon Pharmaceuticals Company Information
- 12.4.2 Beacon Pharmaceuticals Business Overview
- 12.4.3 Beacon Pharmaceuticals Revenue in Afatinib Maleate Tablets Business (2021-2026)
- 12.4.4 Beacon Pharmaceuticals Afatinib Maleate Tablets Product Portfolio
- 12.4.5 Beacon Pharmaceuticals Recent Developments
- 12.5 Kelun－Kazpharm
- 12.5.1 Kelun－Kazpharm Company Information
- 12.5.2 Kelun－Kazpharm Business Overview
- 12.5.3 Kelun－Kazpharm Revenue in Afatinib Maleate Tablets Business (2021-2026)
- 12.5.4 Kelun－Kazpharm Afatinib Maleate Tablets Product Portfolio
- 12.5.5 Kelun－Kazpharm Recent Developments
- 12.6 Hansoh Pharmaceuticak
- 12.6.1 Hansoh Pharmaceuticak Company Information
- 12.6.2 Hansoh Pharmaceuticak Business Overview
- 12.6.3 Hansoh Pharmaceuticak Revenue in Afatinib Maleate Tablets Business (2021-2026)
- 12.6.4 Hansoh Pharmaceuticak Afatinib Maleate Tablets Product Portfolio
- 12.6.5 Hansoh Pharmaceuticak Recent Developments
- 12.7 Chia Tai-Tianqing
- 12.7.1 Chia Tai-Tianqing Company Information
- 12.7.2 Chia Tai-Tianqing Business Overview
- 12.7.3 Chia Tai-Tianqing Revenue in Afatinib Maleate Tablets Business (2021-2026)
- 12.7.4 Chia Tai-Tianqing Afatinib Maleate Tablets Product Portfolio
- 12.7.5 Chia Tai-Tianqing Recent Developments
- 12.8 Boehringer Ingelheim International GmbH
- 12.8.1 Boehringer Ingelheim International GmbH Company Information
- 12.8.2 Boehringer Ingelheim International GmbH Business Overview
- 12.8.3 Boehringer Ingelheim International GmbH Revenue in Afatinib Maleate Tablets Business (2021-2026)
- 12.8.4 Boehringer Ingelheim International GmbH Afatinib Maleate Tablets Product Portfolio
- 12.8.5 Boehringer Ingelheim International GmbH Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst